---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-008852"
form_type: "8-K"
ticker: null
cik: "0001839133"
company_name: "IR-Med, Inc."
filed_at: "2024-03-05T23:59:59+00:00"
generated_at: "2026-06-05T04:05:42.760424+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# IR-Med appoints co-founder Aharon Klein as Interim CEO effective Feb. 28, 2024

## Summary
- Aharon Klein, age 60, currently CTO and co-founder, becomes Interim CEO of IR-Med and its Israeli subsidiary.
- Klein co-founded IR-Med in 2013, served as COO until 2020, then CTO; prior experience includes FertiliGent and a medical device startup.
- Klein continues under same service provider agreement with no disclosed change in compensation terms.

## SEC filing metadata
- accession: 0001493152-24-008852
- form_type: 8-K
- cik: 0001839133
- company_name: IR-Med, Inc.
- filed_at: 2024-03-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1839133/000149315224008852/0001493152-24-008852-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1839133/000149315224008852/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-008852
- JSON: https://secwatch.observer/filing/0001493152-24-008852.json
- Plain text: https://secwatch.observer/filing/0001493152-24-008852.txt

## Key facts
- Executive change
  Aharon Klein was appointed as Interim Chief Executive Officer at IR-Med, Inc..
  - Action: appointed
  - Role: Interim Chief Executive Officer
  source text: appointed Mr. Aharon Klein Chief Technology Officer and a cofounder of the company to serve as its Interim Chief Executive Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1839133/000149315224008852/0001493152-24-008852-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.